J Vis Exp. 2026 Jul 31;(233). doi: 10.3791/71630.
ABSTRACT
Salidroside exerts a broad spectrum of pharmacological activities and represents a promising drug candidate for multiple ailments, including myocardial ischemia-reperfusion injury, acute lung injury, and Alzheimer's disease; nonetheless, quantitative and systematic overviews mapping its full research landscape remain inadequate. In this study, relevant publications from 2000 to 2025 were retrieved from the Web of Science Core Collection. Bibliometric and visual analyses were conducted using CiteSpace and Microsoft Excel. A total of 1400 eligible papers were included. Annual publication output increased gradually before 2010 and accelerated thereafter. Investigators across 62 countries have contributed to this field, with core research clusters centered at institutions such as China Pharmaceutical University. Keyword co‑occurrence analysis reveals that research hotspots center on salidroside's anti-inflammatory, antioxidant, and anti-apoptotic properties, and research has increasingly focused on respiratory, neurological, and cardiovascular disorders through modulation of NF-κB, HIF-1α, and NLRP3 signaling cascades. Meanwhile, salidroside production has evolved from conventional herbal extraction toward industrial fermentation, and its pharmacological exploration has expanded beyond anti‑aging and anti‑hypoxia bioactivity to encompass anti‑tumor efficacy and multi‑organ protection.
PMID:42612095 | DOI:10.3791/71630